KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) FCF Margin (2016 - 2026)

Bio-Rad Laboratories has reported FCF Margin over the past 18 years, most recently at 13.19% for Q1 2026.

  • Quarterly FCF Margin fell 312.0% to 13.19% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 13.79% through Mar 2026, down 20.0% year-over-year, with the annual reading at 14.5% for FY2025, 322.0% up from the prior year.
  • FCF Margin was 13.19% for Q1 2026 at Bio-Rad Laboratories, down from 17.18% in the prior quarter.
  • Over five years, FCF Margin peaked at 18.99% in Q3 2024 and troughed at 2.44% in Q3 2022.
  • The 5-year median for FCF Margin is 9.22% (2023), against an average of 9.41%.
  • Year-over-year, FCF Margin plummeted -2864bps in 2022 and then skyrocketed 1147bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 6.13% in 2022, then dropped by -7bps to 5.69% in 2023, then surged by 114bps to 12.18% in 2024, then surged by 41bps to 17.18% in 2025, then decreased by -23bps to 13.19% in 2026.
  • Per Business Quant, the three most recent readings for BIO's FCF Margin are 13.19% (Q1 2026), 17.18% (Q4 2025), and 13.66% (Q3 2025).